Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

Moreau, P.; Joshua, D.; Chng, W-J; Palumbo, A.; Goldschmidt, H.; Hajek, R.; Facon, T.; Ludwig, H.; Pour, L.; Niesvizky, R.; Oriol, A.; Rosinol, L.; Suvorov, A.; Gaidano, G.; Pika, T.; Weisel, K.; Goranova-Marinova, V.; Gillenwater, H. H.; Mohamed, N.; Aggarwal, S.; Feng, S.; Dimopoulos, M. A.

dc.contributor.author	Weisel, Katja
dc.date.accessioned	2018-06-14T12:52:00Z
dc.date.available	2018-06-14T12:52:00Z
dc.date.issued	2017
dc.identifier.issn	1476-5551
dc.identifier.uri	http://hdl.handle.net/10900/82749
dc.language.iso	en	de_DE
dc.publisher	Nature Publishing Group	de_DE
dc.relation.uri	http://dx.doi.org/10.1038/leu.2016.186	de_DE
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject.ddc	610	de_DE
dc.title	Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study	de_DE
dc.type	Article	de_DE
utue.quellen.id	20170815222223_02251
utue.publikation.seiten	115-122	de_DE
utue.personen.roh	Moreau, P.
utue.personen.roh	Joshua, D.
utue.personen.roh	Chng, W-J
utue.personen.roh	Palumbo, A.
utue.personen.roh	Goldschmidt, H.
utue.personen.roh	Hajek, R.
utue.personen.roh	Facon, T.
utue.personen.roh	Ludwig, H.
utue.personen.roh	Pour, L.
utue.personen.roh	Niesvizky, R.
utue.personen.roh	Oriol, A.
utue.personen.roh	Rosinol, L.
utue.personen.roh	Suvorov, A.
utue.personen.roh	Gaidano, G.
utue.personen.roh	Pika, T.
utue.personen.roh	Weisel, K.
utue.personen.roh	Goranova-Marinova, V.
utue.personen.roh	Gillenwater, H. H.
utue.personen.roh	Mohamed, N.
utue.personen.roh	Aggarwal, S.
utue.personen.roh	Feng, S.
utue.personen.roh	Dimopoulos, M. A.
dcterms.isPartOf.ZSTitelID	Leukemia	de_DE
dcterms.isPartOf.ZS-Issue	1	de_DE
dcterms.isPartOf.ZS-Volume	31	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE